Suppr超能文献

750毫升储雾罐用于儿童吸入性糖皮质激素给药的潜在价值。

The potential value of a 750-ml spacer for the administration of inhaled corticosteroids to children.

作者信息

Reiser J, Frame M H, Warner J O

出版信息

Pediatr Pulmonol. 1986 Jul-Aug;2(4):237-43. doi: 10.1002/ppul.1950020412.

Abstract

An open, cross-over trial was conducted on 25 asthmatic children, aged 6-13 years, who required inhaled steroids. They inhaled Budesonide 200 micrograms twice daily, either directly from the metered dose inhaler or via the pear spacer (PS), for 2 months on each, in randomized order. The effects of the treatment were monitored with diary cards recording peak expiratory flow rates twice daily, symptoms and treatment taken, and with monthly clinical assessments including more sensitive lung function studies (flow-volume loops and single breath nitrogen wash-out tests). There was no specifically PS-related improvement in symptoms or in the majority of tests, but the results showed improvement with time when using either method. The improvement was more distinct in some tests reflecting proximal airway calibre (i.e., PEFR) than in tests thought to reflect predominantly peripheral airway calibre (i.e., F50, RV). The bronchodilator responsiveness, as shown by the increase in lung function tests after a beta-agonist was given, was significantly greater for FVC during the periods when the PS was used, although there was no significant improvement in FEV2 or PEFR. The improvement in tests reflecting proximal airways may have been due to optimization of the inhalation technique, greater understanding of asthma, or better compliance with medication associated with regular attendance for the study. The greater bronchodilator response whilst children were inhaling budesonide by the PS may have been due to increased deposition or better distribution of the steroid but was probably related to a difference between the two groups in initial baseline function tests.

摘要

对25名年龄在6至13岁、需要吸入类固醇的哮喘儿童进行了一项开放性交叉试验。他们随机依次每日两次吸入200微克布地奈德,一次直接从定量吸入器吸入,另一次通过梨形储雾罐(PS)吸入,每种方式各持续2个月。通过日记卡监测治疗效果,日记卡记录每日两次的呼气峰值流速、症状和所接受的治疗,以及每月进行临床评估,包括更敏感的肺功能研究(流量-容积环和单次呼吸氮洗脱试验)。在症状或大多数测试中,没有发现与PS特别相关的改善,但结果显示,无论使用哪种方法,随着时间推移都有改善。在一些反映近端气道口径的测试(即呼气峰值流速)中,改善比在主要反映外周气道口径的测试(即F50、残气量)中更明显。给予β受体激动剂后肺功能测试显示的支气管扩张反应性,在使用PS期间,用力肺活量(FVC)的改善显著更大,尽管第一秒用力呼气容积(FEV2)或呼气峰值流速(PEFR)没有显著改善。反映近端气道的测试中的改善可能是由于吸入技术的优化、对哮喘的更好理解,或与定期参加研究相关的更好的药物依从性。儿童通过PS吸入布地奈德时更大的支气管扩张反应可能是由于类固醇沉积增加或分布更好,但可能与两组在初始基线功能测试中的差异有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验